Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ionis Pharmaceuticals
Biotech
Novartis Lp(a) drug fails closely watched ph. 3 trial
Lp(a) is a known cardiovascular risk factor, but lowering it in the 8,323-patient trial didn't reduce the risk of heart attacks and strokes.
Darren Incorvaia
Sep 4, 2026 9:18pm
Fierce Pharma
Ionis scores ‘breakthrough’ rare disease approval
Sep 4, 2026 11:18am
Don't count out Alnylam's next-gen silencer in ATTR-CM: analysts
Sep 1, 2026 1:55pm
AAIC: Biogen bolsters hopes for pivotal anti-tau push
Jul 14, 2026 9:15am
Roche ends 2 Huntington’s programs, including Ionis ASO
Jul 9, 2026 2:40pm
Ionis bags $30M from Recordati for ex-US rare disease rights
Jun 25, 2026 6:59am
